as15

Peptideexperimental

Clinical trial activity

7 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2009 (NCT00952692)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • UnclearImmunity, active

    Unclear immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • as15

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02364492Phase 1Feb 1, 2015Institut Pasteur
NCT01853878Phase 2Jun 1, 2013GlaxoSmithKline
NCT01266603Phase 2Feb 1, 2012GlaxoSmithKline, University of Texas at Houston
NCT01380145Phase 1Sep 1, 2011Cornell University, GlaxoSmithKline, Icahn School of Medicine at Mount Sinai, Ludwig Institute for Cancer Research, New York University, Temple University
NCT01435356Phase 2Aug 1, 2011EAU Research Foundation, European Association of Urology Research Foundation, GlaxoSmithKline
NCT01425749Early Phase 1 (Phase 1)Jun 1, 2011GlaxoSmithKline, University of Virginia
NCT00952692Phase 1/Phase 2 (Phase 2)Jul 1, 2009Duke University, GlaxoSmithKline
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit6122009
Cornell UniversityAcademic/Hospital1012011
Duke UniversityAcademic/Hospital1112009
EAU Research FoundationAcademic/Hospital1012011
European Association of Urology Research FoundationAcademic/Hospital1112011
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012011
Institut PasteurAcademic/Hospital1112015
Ludwig Institute for Cancer ResearchAcademic/Hospital1112011
New York UniversityAcademic/Hospital1012011
Temple UniversityAcademic/Hospital1012011
University of Texas at HoustonAcademic/Hospital1112012
University of VirginiaAcademic/Hospital1112011
12 organizations
Page 1 / 1